RecruitingPhase 3NCT06055257

Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible

Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible, a Pilot Randomized Control Trial


Sponsor

Sunnybrook Health Sciences Centre

Enrollment

24 participants

Start Date

Jan 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Radiation is commonly used to treat cancer in the head and neck, however, this can lead to a serious complication called osteoradionecrosis (ORN), where there is necrotic (dead) open bone inside or outside of the mouth. This complication is difficult to treat, involves large healthcare costs, and can have devastating effects on quality of life. Two common adjuncts used in treatment of ORN are hyperbaric oxygen therapy (HBOT), which may requires up to 60 treatments at a specialized clinic where patients are treated with high concentrations of oxygen using special chambers, and a less complex option called PENTOCLO which involves treating patients with several antibiotics followed by a combination of other oral medications taken for at least 1 year. This pilot study will be guide the design of a definitive trial to examine if the combination of HBOT and a modified PENTOCLO protocol together is better than the current standard treatment of HBOT alone. Outcomes will include pain, side effects and the need for surgery in patients with ORN. Specifically, the results of this small, pilot study will help to inform the design of a future larger study.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) with a drug regimen called PENTOCLO to treat osteoradionecrosis of the jaw — a painful condition where jawbone tissue dies after radiation therapy for head and neck cancer. **You may be eligible if...** - You have been diagnosed with osteoradionecrosis of the jaw after completing radiation therapy - You have exposed, non-healing bone of more than 20 mm² in the jaw area - You are cleared by a hyperbaric physician and can commit to 60 treatment sessions - You have no medical contraindications to hyperbaric oxygen therapy **You may NOT be eligible if...** - You are pregnant or of childbearing age without using effective contraception - You have conditions that make hyperbaric oxygen unsafe (e.g., certain lung conditions, claustrophobia) - You are currently on medications that interact with study drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGmodified PENTOCLO (mPENTOCLO)

4-week "pre-treatment" phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient. This is followed by an additional 11 months (12 months total) "treatment" phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added.

DRUGsham mPENTOCLO

4-week "pre-treatment" phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient. This is followed by an additional 11 months (12 months total) of sham "treatment" phase (placebo).


Locations(1)

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06055257


Related Trials